BC
IONS icon

Boxer Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Boxer Capital’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-312,000
Closed -$13.8M – 28
2018
Q1 		$13.8M Sell
312,000
-138,000
-31% -$7.01M 1.47% 20
2017
Q4 		$22.6M Buy
+450,000
New +$24.7M 4.14% 8

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Boxer Capital's IONS Position: Q2 2018 in Review

Boxer Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2018, closing a stake of 312,000 shares — an estimated $13.8M sold.

Boxer Capital first reported a position in IONS in Q4 2017 and held it in 2 quarters. The position peaked at $22.6M in Q4 2017. 307 funds tracked by Wall St. Rank hold IONS as of Q2 2018.

  • Boxer Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Boxer Capital sold 312,000 Ionis Pharmaceuticals shares in Q2 2018, an estimated $13.8M.
  • Boxer Capital first reported a position in Ionis Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Boxer Capital's Ionis Pharmaceuticals position peaked at $22.6M in Q4 2017.
  • 307 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2018.

Based on Boxer Capital's 13F filing for Q2 2018, filed 14 Aug 2018.